|
1
|
Zaizen Y, Azuma K, Kurata S, Sadashima E,
Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T,
et al: Prognostic significance of total lesion glycolysis in
patients with advanced non-small cell lung cancer receiving
chemotherapy. Eur J Radiol. 81:4179–4184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
UyBico SJ, Wu CC, Suh RD, Le NH, Brown K
and Krishnam MS: Lung cancer staging essentials: The new TNM
staging system and potential imaging pitfalls. Radiographics.
30:1163–1181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Rens MT, de la Rivière AB, Elbers HR
and van Den Bosch JM: Prognostic assessment of 2,361 patients who
underwent pulmonary resection for non-small cell lung cancer, stage
I, II, and IIIA. Chest. 117:374–379. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pignon JP, Tribodet H, Scagliotti GV,
Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell
R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled
analysis by the LACE Collaborative Group. J Clin Oncol.
26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee P, Weerasuriya DK, Lavori PW, Quon A,
Hara W, Maxim PG, Le QT, Wakelee HA, Donington JS, Graves EE and
Loo BW Jr: Metabolic tumor burden predicts for disease progression
and death in lung cancer. Int J Radiat Oncol Biol Phys. 69:328–333.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Larson SM, Erdi Y, Akhurst T, Mazumdar M,
Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung
HW, et al: Tumor treatment response based on visual and
quantitative changes in global tumor glycolysis using PET-FDG
imaging. The visual response score and the change in total lesion
glycolysis. Clin Positron Imaging. 2:159–171. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Burger IA, Casanova R, Steiger S, Husmann
L, Stolzmann P, Huellner MW, Curioni A, Hillinger S, Schmidtlein CR
and Soltermann A: 18F-FDG PET/CT of non-small cell lung carcinoma
under neoadjuvant chemotherapy: Background based adaptive-volume
metrics outperform TLG and MTV in predicting histopathological
response. J Nucl Med. 57:849–854. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rizk NP, Tang L, Adusumilli PS, Bains MS,
Akhurst TJ, Ilson D, Goodman K and Rusch VW: Predictive value of
initial PET-SUVmax in patients with locally advanced esophageal and
gastroesophageal junction adenocarcinoma. J Thorac Oncol.
4:875–879. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoekstra CJ, Paglianiti I, Hoekstra OS,
Smit EF, Postmus PE, Teule GJ and Lammertsma AA: Monitoring
response to therapy in cancer using
[18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography:
An overview of different analytical methods. Eur J Nucl Med.
27:731–743. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Merlin T, Visvikis D, Fernandez P and
Lamare F: A novel partial volume effects correction technique
integrating deconvolution associated with denoising within an
iterative PET image reconstruction. Med Phys. 42:804–819. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moule RN, Kayani I, Prior T, Lemon C,
Goodchild K, Sanghera B, Wong WL and Saunders MI: Adaptive
18fluoro-2-deoxyglucose positron emission tomography/computed
tomography-based target volume delineation in radiotherapy planning
of head and neck cancer. Clin Oncol (R Coll Radiol). 23:364–371.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Crivellaro C, Signorelli M, Guerra L, De
Ponti E, Buda A, Dolci C, Pirovano C, Todde S, Fruscio R and Messa
C: 18F-FDG PET/CT can predict nodal metastases but not recurrence
in early stage uterine cervical cancer. Gynecol Oncol. 127:131–135.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Adebonojo SA, Bowser AN, Moritz DM and
Corcoran PC: Impact of revised stage classification of lung cancer
on survival: A military experience. Chest. 115:1507–1513. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gadgeel SM, Ramalingam SS and Kalemkerian
GP: Treatment of lung cancer. Radiol Clin North Am. 50:961–974.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grivaux M, Zureik M, Marsal L, Asselain B,
Peureux M, Chavaillon JM, Prudhomme A, Carbonnelle M, Goarant E,
Maury B, et al: Five-year survival for lung cancer patients managed
in general hospitals. Rev Mal Respir. 26:37–44. 2009.(In French).
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Socinski MA, Morris DE, Masters GA and
Lilenbaum R; American College of Chest Physicians, :
Chemotherapeutic management of stage IV non-small cell lung cancer.
Chest. 123 1 Suppl:226S–243S. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lally BE, Geiger AM, Urbanic JJ, Butler
JM, Wentworth S, Perry MC, Wilson LD, Horton JK, Detterbeck FC,
Miller AA, et al: Trends in the outcomes for patients with limited
stage small cell lung cancer: An analysis of the surveillance,
epidemiology, and end results database. Lung Cancer. 64:226–231.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bandoh S, Fujita J, Ueda Y, Fukunaga Y,
Dohmoto K, Hojo S, Yang Y, Yamaji Y, Takahara J and Ishida T:
Expression of carcinoembryonic antigen in peripheral-or
central-located small cell lung cancer: Its clinical significance.
Jpn J Clin Oncol. 31:305–310. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW,
Chung JK, Kim EE and Lee DS: Prognostic value of metabolic tumor
volume and total lesion glycolysis in head and neck cancer: A
systematic review and meta-analysis. J Nucl Med. 55:884–890. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guy MS, Jacob C, McDonald SD, Dowdy YG and
Kardan A: 18F-FDG PET/CT metabolic variability in
functioning oncocytic parathyroid adenoma with brown tumors. Clin
Nucl Med. 39:393–395. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu HX, Chen T, Wang WQ, Wu CT, Liu C, Long
J, Xu J, Zhang YJ, Chen RH, Liu L and Yu XJ: Metabolic tumour
burden assessed by 18F-FDG PET/CT associated with serum CA19-9
predicts pancreatic cancer outcome after resection. Eur J Nucl Med
Mol Imaging. 41:1093–1102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liao S, Penney BC, Wroblewski K, Zhang H,
Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, et al:
Prognostic value of metabolic tumor burden on 18F-FDG PET in
nonsurgical patients with non small cell lung cancer. Eur J Nucl
Med Mol Imaging. 39:27–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chung HW, Lee KY, Kim HJ, Kim WS and So Y:
FDG PET/CT metabolic tumor volume and total lesion glycolysis
predict prognosis in patients with advanced lung adenocarcinoma. J
Cancer Res Clin Oncol. 140:89–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Melloni G, Gajate AM, Sestini S,
Gallivanone F, Bandiera A, Landoni C, Muriana P, Gianolli L and
Zannini P: New positron emission tomography derived parameters as
predictive factors for recurrence in resected stage I non-small
cell lung cancer. Eur J Surg Oncol. 39:1254–1261. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang H, Wroblewski K, Liao S, Kampalath
R, Penney BC, Zhang Y and Pu Y: Prognostic value of metabolic tumor
burden from (18)F-FDG PET in surgical patients with non-small-cell
lung cancer. Acad Radiol. 20:32–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K,
Ahn YC, Kim J, Shim YM and Choi JY: Volume-based assessment by
(18)F-FDG PET/CT predicts survival in patients with stage III
non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 41:50–58.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Usmanij EA, de Geus-Oei LF, Troost EG,
Peters-Bax L, van der Heijden EH, Kaanders JH, Oyen WJ, Schuurbiers
OC and Bussink J: 18F-FDG PET early response evaluation of locally
advanced non-small cell lung cancer treated with concomitant
chemoradiotherapy. J Nucl Med. 54:1528–1534. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vargas HA, Burger IA, Goldman DA, Miccò M,
Sosa RE, Weber W, Chi DS, Hricak H and Sala E: Volume-based
quantitative FDG PET/CT metrics and their association with optimal
debulking and progression-free survival in patients with recurrent
ovarian cancer undergoing secondary cytoreductive surgery. Eur
Radiol. 25:3348–3353. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gallicchio R, Mansueto G, Simeon V,
Nardelli A, Guariglia R, Capacchione D, Soscia E, Pedicini P,
Gattozzi D, Musto P and Storto G: F-18 FDG PET/CT quantization
parameters as predictors of outcome in patients with diffuse large
B-cell lymphoma. Eur J Haematol. 92:382–389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee JW, Kang CM, Choi HJ, Lee WJ, Song SY,
Lee JH and Lee JD: Prognostic value of metabolic tumor volume and
total lesion glycolysis on preoperative 18F-FDG PET/CT
in patients with pancreatic cancer. J Nucl Med. 55:898–904. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chung HH, Kim JW, Han KH, Eo JS, Kang KW,
Park NH, Song YS, Chung JK and Kang SB: Prognostic value of
metabolic tumor volume measured by FDG PET/CT in patients with
cervical cancer. Gynecol Oncol. 120:270–274. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Seol YM, Kwon BR, Song MK, Choi YJ, Shin
HJ, Chung JS, Cho GJ, Lee JC, Lee BJ, Wang SG, et al: Measurement
of tumor volume by PET to evaluate prognosis in patients with head
and neck cancer treated by chemo-radiation therapy. Acta Oncol.
49:201–208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moon SH, Hyun SH and Choi JY: Prognostic
significance of volumebased PET parameters in cancer patients.
Korean J Radiol. 14:1–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vu CC, Matthews R, Kim B, Franceschi D,
Bilfinger TV and Moore WH: Prognostic value of metabolic tumor
volume and total lesion glycolysis from 18F-FDG PET/CT
in patients undergoing stereotactic body radiation therapy for
stage I non-small-cell lung cancer. Nucl Med Commun. 34:959–963.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim K, Kim SJ, Kim IJ, Kim YS, Pak K and
Kim H: Prognostic value of volumetric parameters measured by F-18
FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl
Med Commun. 33:613–620. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Machtay M, Duan F, Siegel BA, Snyder BS,
Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A,
et al: Prediction of survival by [18F]fluorodeoxyglucose positron
emission tomography in patients with locally advanced
non-small-cell lung cancer undergoing definitive chemoradiation
therapy: Results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol.
31:3823–3830. 2013. View Article : Google Scholar : PubMed/NCBI
|
